Proteomic Biomarker Discovery in Cerebrospinal Fluid for MS and NMO Differentiation

A proteomic analysis of cerebrospinal fluid from patients with multiple sclerosis (MS) and neuromyelitis optica (NMO). The dataset contains results from a study that identified 3,816 proteins and validated CD74 and CD14 as disease-specific biomarkers. It was authored by Mengyang Ding and last updated on 2026-04-30.

Use Cases

• Train classification models to differentiate MS from NMO based on proteomic signatures.
• Validate biomarker candidates like CD74 and CD14 using the provided ELISA validation data.
• Analyze disease-specific molecular pathways such as glycosylation alterations in MS or hemostasis-related pathways in NMO.
• Investigate low-abundance protein enrichment strategies (LAPE) for biomarker discovery in biofluids.

Strengths

• Deep proteome coverage of 3,816 proteins identified in cerebrospinal fluid.
• Includes validation results from an independent cohort with AUC scores (0.75 for CD74, 0.72 for CD14).
• Employs a nanoparticle-based low-abundance protein enrichment strategy (LAPE) to uncover additional pathways.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data may reflect temporal or cohort bias inherent to the specific study design.

Provenance

Source

figshare

Collection Method

Comprehensive proteomic analysis of CSF using conventional proteomics and a nanoparticle-based enrichment strategy (LAPE), validated by ELISA.

Time Range

null

Freshness

Last updated 2026-04-30 14:34:29; freshness should be verified.

Geography

null